![]() |
16th May 2008 @ 11:12am |
| Subscribe | Instructions To Authors | Advertising/Supplements | Contact Us | Help |
|
Volume 1, Number 1, March 2000Blockade of the renin-angiotensin-aldosterone system and renal protection in diabetes mellitus A clinical diagnosis of diabetic nephropathy is made in patients with diabetes on the basis of persistent albuminuria (>300 mg/24-hour), the presence of diabetic retinopathy, and the absence of any clinical or laboratory evidence of other kidney or renal tract disease. This definition is valid in patients with either Type 1 or Type 2 diabetes. The clinical syndrome termed diabetic nephropathy is characterised by persistent albuminuria, early arterial blood pressure elevation, a relentless decline in glomerular filtration rate (GFR), and high risk of cardiovascular morbidity and mortality. Previous studies have found a cumulative incidence of diabetic nephropathy of 25–40% after diabetes duration of at least 25 years in both Type 1 and Type 2 diabetes. Diabetic nephropathy has become the leading cause (25–42%) of end-stage renal disease (ESRD) in Europe, Japan, and the United States. Unfortunately, the proportion of ESRD patients suffering from diabetes, particularly Type 2, is expected to rise significantly because the worldwide prevalence of diabetes is expected to double within the next 15 years, and because the individual diabetic patient lives longer and consequently has a greater risk of developing late complications including diabetic nephropathy. JRAAS 2000;1:30-31. View full PDF article (open in new window) Right click on this DOI link and copy link to cite this article (What is a DOI link?) |